A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis
NCT ID: NCT04612699
Last Updated: 2025-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
123 participants
INTERVENTIONAL
2021-03-11
2022-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis
NCT06972888
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
NCT04894890
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
NCT03066609
A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
NCT07150988
A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
NCT05357755
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Jaktinib 50mg Bid
Jaktinib 50mg Bid+ Placebo 50mg Bid+ Placebo 75mg Bid
Jaktinib
Administered orally
Placebo
Administered orally
Jaktinib 75mg Bid
Jaktinib 75mg Bid+ Placebo 50mg\*2 Bid
Jaktinib
Administered orally
Placebo
Administered orally
Jaktinib 100mg Bid
Jaktinib 50mg\*2 Bid+ Placebo 75mg Bid
Jaktinib
Administered orally
Placebo
Administered orally
Placebo
Placebo 50mg\*2 Bid+ Placebo 75mg Bid
Placebo
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Jaktinib
Administered orally
Placebo
Administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* You must have active chronic plaque psoriasis for at least 6 months prior to entry into the study；
* You must have active plaque psoriasis covering at least 10% body surface area； You must have Psoriasis Area and Severity Index (PASI) score of at least 12；You must have Static Physician's Global Assessment (sPGA) score of at least 3；
* The patient can communicate well with the investigator and follow the research and follow-up procedures；
* Understand and voluntarily sign the informed consent form.
Exclusion Criteria
* You must not have received a phototherapy within 4 weeks prior to entry into the study；
* You must not have a history of active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)；
* You must not have a history of chronic alcohol abuse or intravenous (IV) drug abuse
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xinghua Gao, PhD
Role: PRINCIPAL_INVESTIGATOR
First Hospital of China Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZGJAK010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.